Comparison of overall survival after neoadjuvant and adjuvant chemotherapy in patients with early breast cancer with immediate breast reconstruction after mastectomy: A retrospective, matched case‑control study
- Chia-Hua Liu
- Jie-Ru Yang
- I-Chen Tsai
- Chiann-Yi Hsu
- Lum Chih Yean
- Chih-Chiang Hung
Affiliations: Division of Breast Surgery, Department of Surgery, Taichung Veterans General Hospital, Taichung 40705, Taiwan, R.O.C., Biostatistics Task Force, Department of Medical Research, Taichung Veterans General Hospital, Taichung 40705, Taiwan, R.O.C.
- Published online on: October 21, 2022 https://doi.org/10.3892/ol.2022.13557
Copyright: © Liu
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Immediate breast reconstruction after mastectomy combined with chemotherapy is the preferred option for patients with early‑stage breast cancer who require both superior clinical and aesthetic outcomes. The present study aimed to determine the survival benefits of neoadjuvant and adjuvant chemotherapy for patients with early‑stage breast cancer who have undergone immediate breast reconstruction after mastectomy in Taiwan. The present study compared overall survival (OS) following neoadjuvant or adjuvant chemotherapy in 139 patients with early‑stage breast cancer who underwent immediate breast reconstruction after mastectomy. Patient data were used retrospectively as an unmatched cohort. Next, 37 neoadjuvant cases were matched with 37 adjuvant controls through 1:1 age‑, clinical stage‑, and molecular subtype‑matching. OS differences between the cases and controls were determined using Kaplan‑Meier survival curve analyses. Here, 77.7 and 81.1% of the unmatched and matched cohort patients were aged <50 years, respectively. Of the matched neoadjuvant cases, 10 (15.6%) reached pathologic complete response after neoadjuvant chemotherapy, whereas 5 (13.5%) neoadjuvant cases succumbed during the study period. The neoadjuvant matched cases demonstrated a significantly poor OS with their adjuvant matched controls (P=0.044); nevertheless, the stratification analysis results demonstrated that the survival differences between the neoadjuvant and the adjuvant controls decreased after matching. Targeted therapy demonstrated the same OS benefits for both the neoadjuvant matched cases and adjuvant matched controls (P=1.000). This study provided matched case‑control evidence for the feasibility of neoadjuvant chemotherapy combined with targeted therapy for patients with early‑stage breast cancer with immediate breast reconstruction after mastectomy in a Taiwanese female population.